Innate Pharma (IPHA) Receivables (2017 - 2025)

Innate Pharma (IPHA) has 9 years of Receivables data on file, last reported at $15.4 million in Q4 2025.

• For the quarter ending Q4 2025, Receivables changed 0.05% year-over-year to $15.4 million; the trailing twelve-month figure through Dec 2025 stood at $15.4 million (changed 0.05% YoY), and the FY2025 full-year result was $15.4 million, changed 0.05% from the prior year.
• Receivables for Q4 2025 stood at $15.4 million, up from $5.6 million in the prior quarter.
• Across five years, Receivables topped out at $71.2 million in Q4 2023 and bottomed at $5.6 million in Q2 2025.
• The 5-year median for Receivables is $37.8 million (2021), against an average of $38.6 million.
• The widest annual swing landed in 2021, when Receivables sank 99.66%; it then jumped 143.46% in 2022.
• A 5-year view of Receivables shows it stood at $22.0 million in 2021, then soared by 143.46% to $53.6 million in 2022, then jumped by 32.99% to $71.2 million in 2023, then tumbled by 78.42% to $15.4 million in 2024, then climbed by 0.05% to $15.4 million in 2025.
• The last three Receivables figures came in at $15.4 million (Q4 2025), $5.6 million (Q2 2025), and $15.4 million (Q4 2024), per Business Quant data.

Peer Comparison